Drugs / GI-4000
Trials 19
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT00837135 | Jan 2008 → Oct 2009 | malignant pancreatic neoplasm | University of Pennsylvania | Withdrawn | No outcome recorded |
| Phase 1/213 trials | ||||||
| Phase 1/2 | NCT03563157 | Sep 2018 → Apr 2019 | colorectal cancer | ImmunityBio, Inc. | Terminated | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03169777 | Aug 2018 → Jan 2019 | colorectal cancer | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03586869 | Jul 2018 → Apr 2019 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03563170 | May 2018 → Aug 2019 | hepatocellular carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded Stop: Enrollment |
| Phase 1/2 | NCT03169738 | Feb 2018 → Jan 2019 | non-small cell lung carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03387111 | Jan 2018 → Apr 2019 | squamous cell carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03387098 | Dec 2017 → Sep 2018 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03169764 | Dec 2017 → Jan 2019 | head and neck squamous cell carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03175666 | Dec 2017 → Jan 2019 | triple-negative breast carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03197584 | Dec 2017 → Feb 2019 | ovarian carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03197571 | Dec 2017 → Jan 2019 | urothelial carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 1/2 | NCT03329248 | Nov 2017 → Aug 2018 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 1/2 | NCT03136406 | Aug → Nov 2017 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 25 trials | ||||||
| Phase 2 | NCT03554109 | Sep 2018 → Jun 2020 | triple-negative breast carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03563144 | Aug 2018 → Dec 2019 | malignant pancreatic neoplasm | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT03574649 | Jun → Aug 2018 | non-small cell lung carcinoma | ImmunityBio, Inc. | Withdrawn | No outcome recorded |
| Phase 2 | NCT01322815 | Oct 2010 → Sep 2014 | colon carcinoma | Georgetown University | Terminated | No outcome recorded Stop: Enrollment |
| Phase 2 | NCT00655161 | Apr 2008 → Nov 2013 | non-small cell lung carcinoma | GlobeImmune | Completed | No outcome recorded |
| Comparator or background therapy2 trials | ||||||
| Phase 1/2 | NCT03387085 Background | Mar 2018 → Sep 2020 | triple-negative breast carcinoma | ImmunityBio, Inc. | Terminated | No outcome recorded |
| Phase 2 | NCT00300950 Comparator | Jan 2006 → Feb 2015 | malignant pancreatic neoplasm | GlobeImmune | Completed | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 21 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | GI-4000 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03387098 ↗ |
| Modality | Vaccine | “The GI-4000 therapeutic vaccine or placebo will be injected under the skin” NCT00300950 ↗ |
| Route | Subcutaneous | “The GI-4000 therapeutic vaccine or placebo will be injected under the skin” NCT00300950 ↗ |